Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040261 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Memantine for Major Depression
A Phase 3 study of Depression, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT00040261 is a Phase 3 study of Depression that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 112 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00040261, a Phase 3 study of Depression, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and effectiveness of the drug memantine for treating major depression. Major depression is a serious public health concern that contributes to significant morbidity and mortality. Despite the availability of a wide range of antidepressant drugs, a proportion of patients with major depression fail to respond to first-line antidepressant treatment, despite adequate dosage, duration, and compliance. Recent studies suggest that the glutamatergic system may play a role in the pathophysiology and treatment of depression. Memantine and other agents which reduce glutamatergic neurotransmission may represent a novel class of antidepressants. The study consists of three phases. In Phase 1, participants will be tapered off all psychiatric medications over a 2-week washout period. In Phase 2, participants will be randomly assigned to receive either memantine or placebo (an inactive pill) three times a day for 8 weeks. Participants who do not respond to the treatment after 8 weeks will be taken off the study and offered standard treatment. Weekly psychiatric evaluations will evaluate treatment response. During Phase 2, participants who respond well to treatment will enter Phase 3, a 16-week continuation phase of either memantine or placebo. Interviews will be conducted every other week in the first month , then monthly thereafter. Participants will have a physical examination, neuropsychological tests, and eye blink tests at baseline and at the end of the study. Pulse, blood pressure, and blood samples will be taken throughout the study. Participants will undergo an electrocardiogram as well as positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain.
Conditions Studied
Interventions
- DRUG Memantine HCL
Study Locations (1)
Maryland
- National Institute of Mental Health (NIMH) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2002-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040261
The ClinicalTrials.gov registry entry for NCT00040261 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (86% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Memantine HCL is the first listed.
NCT00040261 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00040261 about?
NCT00040261 is a clinical study titled "Clinical Trial of Memantine for Major Depression". The purpose of this study is to determine the safety and effectiveness of the drug memantine for treating major depression. Major depression is a serious public health concern that contributes to significant morbidity and mortality. Despite the availability of a wide range of antidepressant drugs, ...
What is the current status of trial NCT00040261?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2002-06. Estimated completion is 2005-03.
What conditions does trial NCT00040261 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00040261?
The interventions under investigation include: Memantine HCL (DRUG).
Who is sponsoring clinical trial NCT00040261?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040261 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.